Journal of Allergy and Hypersensitivity Diseases最新文献

{"title":"Ribociclib-induced drug reaction with eosinophilia and systemic symptoms syndrome: report of two cases","authors":"Aline Garcia,&nbsp;Benoît Ben-Said","doi":"10.1016/j.jahd.2026.100072","DOIUrl":"10.1016/j.jahd.2026.100072","url":null,"abstract":"<div><h3>Background</h3><div>Ribociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, is widely used for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Drug reaction with eosinophilia and systemic symptoms is a rare but serious drug hypersensitivity reaction that has been only exceptionally reported with CDK4/6 inhibitors.</div></div><div><h3>Cases</h3><div>We describe two cases of ribociclib-induced drug reaction with eosinophilia and systemic symptoms syndrome, with onset 3 to 6 months after ribociclib initiation, presenting with cutaneous eruption, eosinophilia, and systemic involvement. Both patients improved after ribociclib discontinuation and corticosteroid therapy. One patient was successfully switched to palbociclib, whereas the other developed hepatotoxicity following the within-class switch to palbociclib.</div></div><div><h3>Conclusions</h3><div>These cases highlight the importance of recognizing drug reaction with eosinophilia and systemic symptoms syndrome as a potential complication of ribociclib therapy and support pharmacovigilance efforts regarding CDK4/6 inhibitor–associated severe cutaneous adverse reactions.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"10 ","pages":"Article 100072"},"PeriodicalIF":0.0,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148737828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world use of sublingual immunotherapy and shared decisions in French observational study PRACTIS","authors":"Habib Chabane ,&nbsp;Isabelle Bossé ,&nbsp;Julien Cottet ,&nbsp;Éric Fromentin ,&nbsp;Sylvie Guillevin ,&nbsp;Josiane Cognet-Sicé ,&nbsp;Silvia Scurati ,&nbsp;Pascal Demoly","doi":"10.1016/j.jahd.2026.100063","DOIUrl":"10.1016/j.jahd.2026.100063","url":null,"abstract":"<div><h3>Background</h3><div>Allergic rhinitis with/without allergic asthma can be treated with sublingual allergen immunotherapy. The PRACTIS study evaluated the short-term benefits of sublingual allergen immunotherapy for patients with allergic rhinitis in current practice in France. Here are specifically described the observed modalities of use and treatment plan.</div></div><div><h3>Methods</h3><div>This prospective, non-interventional, longitudinal, multicentre study was conducted in patients at least 5-years-old, with clinically significant confirmed allergic rhinitis to one or more allergens and eligible for sublingual allergen immunotherapy. Patients’ data were recorded at inclusion and after 6 (seasonal allergy) or 12 (perennial allergy) months of sublingual allergen immunotherapy.</div></div><div><h3>Results</h3><div>Sublingual allergen immunotherapy was prescribed in 1587 patients (mean age 25.8 ± 15.6 years, 52.7 % female) and 1047 (66.0 %) attended the end-of-study visit to assess the benefits and satisfaction with sublingual allergen immunotherapy. Most (87.4 %) patients had moderate-to-severe persistent allergic rhinitis, 31.8 % had allergi asthma and 50.8 % were polyallergic. The main reasons for prescribing sublingual allergen immunotherapy were discomfort severity (85.4 %) and type of allergic symptoms (80.2 %). Patients were involved in the treatment choice in 68.7 % of cases. A single sublingual allergen immunotherapy was prescribed to 88.0 % of patients, mainly in liquid form (71.8 %), most frequently house dust mite or grass pollen allergen extracts. Physician–patient agreement on satisfaction with sublingual allergen immunotherapy was greater than 80 % for monoallergic and polyallergic patients at end-of-study. Overall, 85.7 % of patients planned to continue treatment and 78.8 % would recommend sublingual allergen immunotherapy to someone else.</div></div><div><h3>Conclusion</h3><div>Sublingual allergen immunotherapy availability in tablet or liquid form, comprising a large number of allergen extracts and dose flexibility, enables treatment personalisation. The shared decision with the patients in the prescription type may improve sublingual allergen immunotherapy adherence and satisfaction.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"9 ","pages":"Article 100063"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147858442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Public health impact of envenomation by Vespa velutina nigrithorax and other Hymenoptera in France: A multisource study","authors":"Sandra Sinno-Tellier ,&nbsp;Jérémy Hamon ,&nbsp;Luc De Haro ,&nbsp;Magali Labadie ,&nbsp;Adrien Maillot ,&nbsp;Nicolas Delcourt ,&nbsp;Roxane Curtet ,&nbsp;Bernadette Verrat ,&nbsp;Anne Fouillet","doi":"10.1016/j.jahd.2026.100062","DOIUrl":"10.1016/j.jahd.2026.100062","url":null,"abstract":"<div><h3>Introduction</h3><div>The yellow-legged hornet, <em>Vespa velutina nigrithorax</em>, is an invasive species native to Asia that has spread rapidly in France and neighboring countries since 2004. The impact of yellow-legged hornet and other Hymenoptera on human health is poorly known, as the latest study was conducted between 2009 and 2013.</div></div><div><h3>Methods</h3><div>A descriptive study of the public health impact of envenomation by yellow-legged hornets and other Hymenoptera in France between January 1, 2014, and December 31, 2023 based on four complementary health data sources: calls to poison control centers, emergency department visits, hospital admissions and death certificates.</div></div><div><h3>Results</h3><div>The temporal distribution of the 6022 cases recorded by poison control centers and the 179,141 emergency department visits for Hymenoptera stings showed no upward or downward trend over the ten-year study period. Seasonality was marked, with a peak of Hymenoptera stings in July and August. Geographical data showed a homogeneous distribution of Hymenoptera stings throughout France. Of the 6022 cases recorded by poison control centers, 37 % involved wasps, 25 % hornets (28 % yellow-legged hornet, 24 % European hornet, 48 % unspecified) and 19 % honeybees; the remaining 19 % involved unspecified Hymenoptera. Hornets presented the highest risk of severe envenomation (2.3 % of hornet stings). Allergic symptoms were observed in 89 % of severe Hymenoptera cases. Of the 18,213 hospital admissions for Hymenoptera stings, 13 % were in intensive care units, seemed to increase from 10 % in 2014 to 17 % in 2023. According to death certificates, 256 people died as a result of a Hymenoptera stings, among which 27 % of hornet stings. Severe Hymenoptera stings most often affected adults over 60 years old.</div></div><div><h3>Conclusion</h3><div>Despite the spread of the yellow-legged hornet in France, no trend in Hymenoptera stings frequency was observed during the study period. However, the percentage of hospital admissions in intensive care units for Hymenoptera stings seemed to increase slightly from 2014 to 2023. In order to monitor their impact on health, a prospective surveillance of Hymenoptera stings could be implemented. Measures to be taken in the event of discovering a wasp or hornet nest near homes or of Hymenoptera stings are essential to disseminate to protect the population.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"9 ","pages":"Article 100062"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147750691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A practical approach to the management of chronic hand eczema: expert insights","authors":"Bruno Halioua ,&nbsp;Florence Tétart ,&nbsp;Camille Leleu ,&nbsp;Ziad Reguiai ,&nbsp;Laurent Misery ,&nbsp;Francoise Giordano ,&nbsp;Marie-Noëlle Crépy ,&nbsp;Annick Barbaud","doi":"10.1016/j.jahd.2026.100061","DOIUrl":"10.1016/j.jahd.2026.100061","url":null,"abstract":"<div><div>Chronic hand eczema is a persistent inflammatory skin condition that significantly affects quality of life, especially in high-risk occupations. Often misdiagnosed as atopic dermatitis, chronic hand eczema has been historically managed inconsistently. Recent insights into its epidemiology, socioeconomic impact, and pathophysiology highlight the need for more targeted approaches. A panel of seven French dermatologists and allergologists independently convened over 6 months, to review current knowledge and develop a practical treatment algorithm for chronic hand eczema in France. Their goal was to align recent evidence with real-life clinical experience. The panel reaffirmed chronic hand eczema’s complex etiology, high occupational prevalence, and psychosocial burden. Updated diagnostic criteria were defined, stressing clinical evaluation, occupational history, and appropriate testing. Subtypes – including irritant, allergic, atopic, and protein contact dermatitis – were addressed, with emphasis on overlapping forms and diagnostic challenges. Treatment strategies were evaluated, distinguishing approved and off-label options available in France. The experts underscored the role of new targeted therapies in moderate-to-severe cases and emphasized prevention through patient education on irritant and allergen avoidance. The resulting algorithm provides a stepwise, pragmatic approach to chronic hand eczema management, tailored to disease severity, phenotype, and treatment response. This expert opinion promotes earlier recognition, multidisciplinary care, and improved management in everyday dermatological practice.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"9 ","pages":"Article 100061"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147397333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient characteristics and treatment satisfaction with 300 IR sublingual allergen immunotherapy for cat allergy: Results from a French survey","authors":"Nhân Pham-Thi ,&nbsp;Luc Colas ,&nbsp;Julien Goret ,&nbsp;Silvia Scurati ,&nbsp;Laurence Girard ,&nbsp;Romain Montagne ,&nbsp;Laurent Guilleminault","doi":"10.1016/j.jahd.2025.100060","DOIUrl":"10.1016/j.jahd.2025.100060","url":null,"abstract":"<div><h3>Introduction</h3><div>Although cat allergy is highly prevalent in the French population, it is often underdiagnosed and undertreated. Allergen immunotherapy can be an effective etiological treatment for cat allergy, but there is limited data on its effectiveness. To investigate patients' perceptions of allergen immunotherapy effectiveness, a survey was conducted in France in a cohort of patients with cat-associated allergic rhinitis with/without mild-to-moderate allergic asthma and treated with cat allergen liquid sublingual immunotherapy.</div></div><div><h3>Methods</h3><div>Patients (5–65 years old) registered in the Stallergenes Greer sublingual immunotherapy dispensation database and treated with 300 IR cat allergen liquid sublingual immunotherapy for more than 12 months were invited to participate in the survey. Data were collected on the patient’s socioeconomic characteristics, past or current cat exposure, allergy history and treatment, and perception of sublingual immunotherapy’s impact on the patient’s health status. Data were analyzed descriptively.</div></div><div><h3>Results</h3><div>Of 617 patients invited to participate in the survey, 197 responded (31.9 %). Most respondents were adults (78.6 %) living in urban areas (64.0 %). The majority (89.8 %) have been suffering from cat allergy for at least 3 years, 86.8 % declared being polyallergic (mainly to house dust mites and pollen), and 63.2 % were receiving multiple treatments. Most respondents (80.8 %) had lived with or were currently living with cats (72.0 % for more than 5 years). Before sublingual immunotherapy initiation, 92 % of patients were using symptomatic medications. The prescription of sublingual immunotherapy was primarily driven by the presence of allergic asthma (61.9 %), followed by allergic rhinitis (54.8 %). Most patients (86.8 %) reported an improvement within the first year of sublingual immunotherapy, particularly regarding rhinitis symptoms (63.2 %), the ability to pet a cat without experiencing symptoms (51.5 %), and a reduction in asthma exacerbations (48.0 %). A significant percentage of patients (59.9 %) reported an improvement in their health status following the initiation of sublingual immunotherapy.</div></div><div><h3>Conclusion</h3><div>The findings from this survey support the clinical benefit of cat sublingual immunotherapy as a valuable therapeutic option for patients with persistent cat allergy symptoms, demonstrating rapid symptom relief and a meaningful improvement in quality of life.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"9 ","pages":"Article 100060"},"PeriodicalIF":0.0,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145799749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of an allergic patient education guide by general practitioners","authors":"Océane Alemany ,&nbsp;Catharina Chatain ,&nbsp;Farouk Bendamene ,&nbsp;Pauline Pralong ,&nbsp;Camille Egeley ,&nbsp;Isabelle Boccon Gibod ,&nbsp;Marie Thérèse Leccia ,&nbsp;Laurence Bouillet ,&nbsp;Alexis Bocquet","doi":"10.1016/j.jahd.2025.100054","DOIUrl":"10.1016/j.jahd.2025.100054","url":null,"abstract":"<div><h3>Background</h3><div>Immediate intramuscular administration of adrenaline with autoinjector devices is the first line treatment of anaphylaxis and requires regular patient education, especially by general practitioners. We evaluated the value of a therapeutic patient education guide as a tool designed for general practitioners.</div></div><div><h3>Objectives and methods</h3><div>We created a therapeutic patient education guide for instruction and training on when and how to use adrenaline autoinjector devices. We assessed the acceptability and feasibility of this tool during consultations by a questionnaire survey.</div></div><div><h3>Results</h3><div>A total of 85 responses were included. Acceptability was demonstrated but not feasibility, due to the unavailability of trainer in adrenaline autoinjector devices and the lack of time to use the guide during medical consultations.</div></div><div><h3>Conclusion</h3><div>This study demonstrates the acceptability of the therapeutic patient education guide for general practitioners but not its feasibility. The involvement of other health professionals and the availability of trainers in adrenaline autoinjector devices could improve this point.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"8 ","pages":"Article 100054"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145571729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Introduction of egg, peanut and tree nuts into infant food in Île-de-France","authors":"Rafael Fajardo Torres ,&nbsp;Ralph Epaud ,&nbsp;Maria Chiara Leoni ,&nbsp;Ariane Nemni ,&nbsp;Guillaume Lezmi","doi":"10.1016/j.jahd.2025.100053","DOIUrl":"10.1016/j.jahd.2025.100053","url":null,"abstract":"<div><h3>Introduction</h3><div>Complementary feeding, with the introduction of 2 g of egg, peanut and tree nut proteins per week into infant food from the age of 4 to 6 months is recommended to prevent the development of allergies to these foods. The adherence of primary care doctors to these recommendations has been little studied.</div></div><div><h3>Objective</h3><div>To evaluate the practices of general practitioners and pediatricians in Île-de-France concerning the introduction of egg, peanut and tree nuts into the diet of infants during complementary feeding.</div></div><div><h3>Methods</h3><div>GPs and pediatricians in IDF completed an anonymous online questionnaire. Total adherence to the recommendations was defined as the introduction of 2 g of egg and peanut proteins per week, or equivalent, from the age of 4 to 5 months, in all children (general and at-risk populations).</div></div><div><h3>Results</h3><div>In total, 121 doctors (61 general practioners, 60 pediatricians) participated in the study. The rates of total adherence to recommendations were 19 % for egg and 4.1 % for peanut. Early introduction (at 4 to 5 months) was recommended by 31.4 % of participants for egg, 27.3 % for peanut and 26.4 % for tree nuts. Only 10.7 % and 2.5 % of doctors recommended the introduction of 2 g of egg or peanut protein/week, respectively. Total adherence to the recommendations was greater for pediatricians than for general practioners (28.3 % versus 9.8 % for egg, <em>p</em> = 0.01; 8.3 % versus 0 % for peanut, <em>p</em> = 0.03). Knowledge of the recommendations was strongly associated with total adherence (for egg, OR = 12.2, <em>p</em> = &lt; 0.001).</div></div><div><h3>Conclusion</h3><div>Rates of total adherence to recommendations for the introduction of egg, peanut and tree nuts are low, with greater adherence to the principle of early introduction than to the amount of protein to be introduced. Total adherence is associated with knowledge of the recommendations. The communication of recommendations to primary care doctors therefore needs to be improved.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"8 ","pages":"Article 100053"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145449226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kounis syndrome induced by wheat food allergy","authors":"Léonore Chardin ,&nbsp;François Touraine ,&nbsp;Élisabeth Bellet-Fraysse ,&nbsp;Camille Coumes-Salomon ,&nbsp;Laurence Lepeltier ,&nbsp;Claire Boulogne ,&nbsp;Benjamin Savoye ,&nbsp;Yann Ollivier ,&nbsp;Habib Chabane","doi":"10.1016/j.jahd.2025.100052","DOIUrl":"10.1016/j.jahd.2025.100052","url":null,"abstract":"<div><div>Kounis syndrome is an allergic acute coronary syndrome. Here we report two cases of Kounis syndrome induced by type E immunoglobulin-mediated wheat allergy. Both patients were sensitized to omega-5 gliadin, a key marker of anaphylaxis to wheat. These cases highlight the importance of considering Kounis syndrome in patients with acute coronary syndrome and allergic symptoms triggered by food allergy.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"8 ","pages":"Article 100052"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145468883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Food anaphylaxis: data from the French Allergy-Vigilance Network, 2002–2022","authors":"Pascale Beaumont ,&nbsp;Martine Morisset ,&nbsp;Sélina Tscheiller ,&nbsp;Éléna Bradatan ,&nbsp;Caroline Klingebiel ,&nbsp;Jean-Marie Renaudin ,&nbsp;Amandine Divaret-Chauveau ,&nbsp;Dominique Sabouraud Leclerc ,&nbsp;Guillaume Pouessel","doi":"10.1016/j.jahd.2025.100051","DOIUrl":"10.1016/j.jahd.2025.100051","url":null,"abstract":"<div><h3>Introduction</h3><div>The number of hospitalizations for food-induced anaphylaxis is rising in industrialized countries. Our aim was to give an overview of food-induced anaphylaxis cases recorded in the French Allergy-Vigilance Network database focusing on the type of allergens, particularities according to elderly people, severity, cofactors, and management.</div></div><div><h3>Methods</h3><div>Food-induced anaphylaxis cases recorded in the Allergy-Vigilance Network database from 2002 to 2022 were analysed retrospectively.</div></div><div><h3>Results</h3><div>Of the 4282 cases of anaphylaxis registered by the Allergy-Vigilance Network, 2842 (66.4 %) cases involved food. Of these, 1591 (52.4 %) were children (under 18 years), 1062 (37.3 %) adults (18 to 59 years) and 189 (6.6 %) people aged ≥ 60 years. Eighteen fatalities have been reported. Tree nuts and peanut together accounted for 34.4 % of allergens, followed by fruits (8.7 %) and legumes (other than peanut) (6.6 %). The most frequent cofactor was physical exercise reported in 57 % of cases in children and 38 % in adults. Adrenaline was administered in 24.4 % of cases. Several allergens should be subject to specific mandatory labeling, particularly goat's and sheep's milk responsible for two deaths.</div></div><div><h3>Conclusion</h3><div>In our database, foods, mainly peanut and tree nuts, represent the most common anaphylaxis triggers and children are involved in more than half of cases. Our data highlight a room for improvement in the management of anaphylaxis, particularly the use of adrenaline. New technological tools, such as artificial intelligence, collaboration with health authorities and other registries are required to address knowledge gaps regarding severe anaphylaxis.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"7 ","pages":"Article 100051"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145465985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Egg allergy: An obstacle to childhood vaccination. Recommendations for vaccination practices","authors":"Juliette Caron ,&nbsp;Alexia Guilbert ,&nbsp;Hugo Devooght ,&nbsp;Patricia Rannaud-Bartaire ,&nbsp;Anne Herman ,&nbsp;Florence Libon ,&nbsp;Christine Delebarre-Sauvage","doi":"10.1016/j.jahd.2025.100045","DOIUrl":"10.1016/j.jahd.2025.100045","url":null,"abstract":"<div><h3>Introduction</h3><div>This study explores the current vaccination practices of French general practitioners regarding children with egg allergy.</div></div><div><h3>Methods</h3><div>An observational survey was carried out in the North of France using a questionnaire intended for volunteer general practioners.</div></div><div><h3>Results</h3><div>Among 93 general practitioners surveyed, the majority (88.9 %) considered egg allergy to be problematic in case of a vaccination. The three most problematic vaccines were those against influenza, yellow fever and measles, mumps and rubella.</div></div><div><h3>Discussion</h3><div>Egg allergy may represent an obstacle to children vaccination. We submit recommendations for vaccination practices.</div></div>","PeriodicalId":100752,"journal":{"name":"Journal of Allergy and Hypersensitivity Diseases","volume":"7 ","pages":"Article 100045"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}